Citations

Clear

1828 citation(s) found for "Su, Emily".

Monoclonal gammopathy of thrombotic significance in a nutshell
Kanack, Adam J. , Mauch, Emily, Murray, David , Padmanabhan, Anand , Mauch, Emily E

Mayo Clinic

British Journal of Haematology | March 17, 2026 | Volume: 208 | Issue: 5 | Pages: 1551-1554

10.1111/bjh.70438 | PMID 41841750 Get It

Summary This nutshell review discusses the pathophysiology, diagnostic features, treatment strategies and avenues for future research in a recently identified thrombotic entity, monoclonal gammopathy of thrombotic significance (MGTS). MGTS is an anti‐platelet factor 4 (PF4) antibody‐mediated disorder distinct from heparin‐induced thrombocytopenia (HIT) and vaccine‐induced thrombotic thrombocytopenia (VITT), as it involves the production of persistent, monoclonal anti‐PF4 antibodies. Several subtypes of MGTS, including ‘HIT‐like’, ‘VITT‐like’ and ‘non‐HIT/VITT‐like’, exhibit unique serological profiles that can complicate diagnosis. Recognition of ‘HIT‐like’ MGTS is critical to avoid heparin exposure in these patients, which can result in adverse effects like those seen in heparin‐exposed HIT patients. ‘Non‐HIT/VITT‐like’ MGTS antibodies have only been detected in PF4‐enhanced functional testing; therefore, we recommend using these platelet‐based tests as the front‐line assay for detecting MGTS antibodies. Mass profiling using mass spectrometry is critical for the ‘fingerprinting’ of monoclonal antibodies to establish a diagnosis of MGTS. Treatments used in HIT and VITT, such as non‐heparin anticoagulants and intravenous immunoglobulin G, are typically insufficient for managing MGTS. Emerging MGTS therapies, such as plasma cell‐directed drugs and Bruton tyrosine kinase inhibitors, are discussed. The review concludes with an emphasis on areas of future research in MGTS.
Landscape of somatic genetic alterations and PAM50 intrinsic subtypes in breast cancer associated with germline pathogenic variants in DNA-repair genes
Yadav, Siddhartha , Reid, Sonya , Yilma, Binyam , Fragkogianni, Stamatina, Whisenant, Jennifer G. , Weidner, Anne , Rajagopal, Padma Sheila , Huang, Minxuan , Mauer, Elizabeth , Arafa, Ali T., Chao, Calvin, Antonarakis, Emmanuel S, Kurian, Allison, Couch, Fergus J, Pal, Tuya, Kurian, Allison W. , Mauer, Elizabeth , Arafa, Ali T. , Arafa, Ali , Teslow, Emily A , Antonarakis, Emmanuel S , Kurian, Allison W , Couch, Fergus J. , Pal, Tuya , Yadav, Siddhartha , Fragkogianni, Stamatina , Weidner, Anne , Chao, Calvin Y. , Teslow, Emily A. , Antonarakis, Emmanuel S. , Couch, Fergus J. , Pal, Tuya

Mayo Clinic

JNCI: Journal of the National Cancer Institute | March 11, 2026 | Volume: 118 | Issue: 8 | Pages: 1416-1424

10.1093/jnci/djag070 | PMID 41832987 Get It

Abstract Background The association of germline pathogenic and likely pathogenic variants (GPVs) in hereditary breast cancer genes with underlying tumor biology and clinical outcomes remains incompletely understood. This study characterized differences in somatic alterations and intrinsic subtypes between sporadic and hereditary breast cancers associated with GPVs in ATM, BRCA1, BRCA2, CHEK2, or PALB2. Methods This retrospective cohort study included women with breast cancer and an ATM, BRCA1, BRCA2, CHEK2, or PALB2 GPV who had undergone tumor sequencing and whole transcriptome RNA expression analysis. Clinicopathological features, intrinsic subtypes, somatic alterations, and survival were compared by GPV status and immunohistochemistry-defined subtype and to sporadic cases. All statistical significance tests were 2-sided. Results The 4988 women with breast cancer in this study included 98 BRCA1, 126 BRCA2, 74 PALB2, 54 ATM, and 83 CHEK2 GPVs. Compared with sporadic cases, hormone receptor–positive/(ERBB2) formerly HER2–negative tumors in BRCA1 GPVs were statistically significantly enriched for basal subtype (45.5% vs 11.4%; P < .001), while CHEK2 carriers had a higher prevalence of luminal A subtype (80.4% vs 60.3%; P = .006). In hormone receptor–positive/(ERBB2)-negative breast cancers, BRCA1 GPVs were enriched for TP53 alterations (84.6% vs 29.8%; q < 0.001), ATM GPVs with FGFR1 alterations (35.4% vs 12.7%; q = 0.04), and BRCA2 GPVs with APC alterations (10.1% vs 1.5%; q = 0.004). Conversely, BRCA2 GPVs were inversely associated with PIK3CA alterations (13.0% vs 34.1%; q = 0.005) and CHEK2 GPVs with TP53 alterations (8.0% vs 29.8%; q = 0.02). Conclusions The GPVs in BRCA1, BRCA2, ATM, CHEK2, and PALB2 are associated with distinct intrinsic breast cancer subtypes and somatic genomic alterations. These findings may enhance precision in risk stratification and guide personalized treatment strategies.
The miR-362-3p/ BCLAF1 axis regulates cisplatin sensitivity and metastatic progression in triple-negative breast cancer
Liu, Zhaoji, Wu, Catherine, Uyemura, Madison M., Sardella, Barbara, Aronson, Emily K, Ke, Shizhong, Massicott, Erica S., Li, Xiaohui, Wang, Lin, Karagkouni, Dimitra, Kalavros, Nikolaos , Bogsan, Cristina S, Zhou, Lihan, Cheng, He, Garber, Judy E, Schnitt, Stuart J. , Tung, Nadine M, Heng, Yujing J., Heng, Yujing J. , Wu, C., Aronson, Emily K., Ke, Shizhong, Li, Xiaohui, Wang, Lin , Karagkouni, Dimitra , Vlachos, Ioannis S. , Batalini, Felipe , Bogsan, Cristina Stewart Bittencourt , Cheong, Jit Kong , Munson, Phillip B. , Mayer, Erica L. , Garber, Judy E. , Tung, Nadine , Kasinski, Andrea L. , Slack, Frank John , Wulf, Gerburg M.

Mayo Clinic

No container title available | March 11, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.03.09.26347941 Get It

Abstract Platinum-based chemotherapy remains a cornerstone of treatment for triple-negative breast cancer (TNBC), yet the molecular determinants governing platinum response remain poorly defined. By leveraging the randomized Phase II INFORM trial, which compared neoadjuvant cisplatin to anthracycline-based therapy in BRCA1/2 -mutant breast cancer—we identified miR-362-3p as a specific regulator of cisplatin sensitivity. Higher plasma miR-362-3p expression was exclusively associated with favorable clinical outcome in the cisplatin arm, with no association observed in the AC arm, decoupling platinum-specific vulnerability from general chemotherapy response. We used gain- and loss-of-function TNBC models to establish that miR-362-3p functions as a potent sensitizer to cisplatin in vitro and in vivo . Integrated TCGA analysis and experimental validation identified BCLAF1, a key regulator of DNA damage response, as a direct repression target of miR-362-3p. We uncovered a novel role for the miR-362-3p/ BCLAF1 axis in overcoming platinum resistance in TNBC.
Improving Efficiency in Patient Access to Medication Assistance Programs
Davis, Julia, Lea, Catherine M., Yost, Kaitlin J. , Nichols, Marisa, Stogdill, Emily R., Hudson, Neil, Wulffson, Courtney K.

Mayo Clinic

Journal of Healthcare Management | March 10, 2026 | Volume: 71 | Issue: 2 | Pages: 140-151

10.1097/jhm-d-24-00192 | PMID 41817542 Get It

SUMMARY Goal: The purpose of this study was to enhance access to medication assistance programs (MAPs), which are crucial for providing free medications to patients who cannot afford them. These programs are particularly beneficial for the management of chronic conditions such as diabetes, heart failure, and cancer, for which medication adherence is vital for positive patient outcomes, and cost is a common barrier. Methods: This quality improvement project aimed at optimizing the MAP enrollment process. Interventions included the development of frequently asked questions documents, standardized templates for documentation, establishment of MAP technician office spaces, and standardization of patient referrals. A Mann-Whitney U test and a chi-square test were used to summarize the data in this study. Principal Findings: The project resulted in a 56% increase in new patient enrollments ( p < .01) and a 33% increase in medications provided, with a significant reduction in the average time from patient referral to application approval. Practical Applications: The project improved patient access to MAPs, optimized pharmacy technician resources, and significantly reduced processing times, an important factor in preventing treatment delays and improving patient care. Future plans include expanding the new enrollment process to annual reenrollments, formally establishing the MAP technician within departments, and considering additional pharmacy technician support in response to increasing demand for MAPs.
Clinical Outcomes and Prognostic Features of Diffuse Hemispheric Glioma, H3 G34-Mutant: An International Multi-institutional Study
Crowell, Cameron , Mankuzhy, Nikhil P. , Bennett, Julie , Bandopadhayay, Pratiti , Sturm, D., Green, Adam L. , Gupta, Tejpal , Chatterjee, Abhishek , Epari, Sridhar , Chinnaswamy, G., Prasad, Maya , Patel, Sonal, MacNeil, Mary , Vanan, Magimairajan , Larouche, Valérie , Renzi, Samuele , Jones, Jacquelyn , Perreault, Sébastien , Mata-Mbemba, Daddy , Sangatsuda, Yuhei , Yoshimoto, Koji , Lin, Emily , Feddersen, Charlotte R., Pavon-Mengual, Miriam, Vizzini, Olivia, Zápotocký, Michal, Popovacki, Aimee, Schlosser, Mary-Pat , Omene, Egiroh , Alexander, Kimberley L., Satgunaseelan, Laveniya, Williams, Andrew , Yao, Kristin, Ronsley, Rebecca , Cheng, Sylvia, Eisenstat, David, Andre, N., Matheson, K., Chan, Aimee , Lim-Fat, Mary Jane, Lapointe, Sarah , Cayrol, Romain , Coleman, Christina , Juretic, Nikoleta , McThenia, Sheila, Khan, Sara , Salloum, Ralph , Galvin, Robert , Hawkins, Cynthia, Karajannis, Matthias A. , Jones, David T.W., Ligon, K. L., Jabado, Nada, Erker, Craig , Sturm, Dominik , Chinnaswamy, Girish , Patel, Sohil H , Vanan, Magimairajan Issai , Feddersen, Charlotte , Cruz, Ofelia , Pavon-Mengual, Miriam , Vizzini, Olivia , Zápotocký, Michal , Popovacki, Aimee , Klawinski, Darren , Hansford, Jordan R , Schlosser, Mary-Pat , Omene, Egiroh , Alexander, Kimberley L , Satgunaseelan, Laveniya , Williams, Andrew , Yao, Kristin , Ronsley, Rebecca , Cheng, Sylvia , Ludlow, Louise , Eisenstat, David , Khuong-Quang, Dong-Anh , Tabouret, Emeline , André, Nicolas , Matheson, Kara , Chan, Aimee , Lim-Fat, Mary Jane , Lapointe, Sarah , Cayrol, Romain , Coleman, Christina , Juretic, Nikoleta , McThenia, Sheila , Khan, Sara , Wright-Nadkarni, Mariah , Salloum, Ralph , Galvin, Robert T , Sener, Ugur , Hawkins, Cynthia , Imber, Brandon S , Karajannis, Matthias A , Jones, David T W , Ligon, Keith L , Jabado, Nada , Erker, Craig , Larouche, Valérie , Hansford, Jordan R. , Satgunaseelan, Laveniya , Sener, Uğur , Hawkins, Cynthia

Mayo Clinic

Clinical Cancer Research | March 9, 2026 | Volume: 32 | Issue: 11 | Pages: 2243-2254

10.1158/1078-0432.ccr-25-3764 | PMID 41801141 Get It

Abstract Purpose: Knowledge of prognostic factors and long-term survival in patients with diffuse hemispheric glioma, H3 G34–mutant (DHG, H3 G34), remains limited in this tumor with a poor prognosis. Experimental Design: This retrospective, multi-institutional study investigated prognostic variables for patients with DHG, H3 G34, and their association with progression-free survival (PFS) and overall survival (OS). Uni- and multivariable Cox proportional hazard models were applied with multiple imputed datasets. Results: A total of 153 patients (142 G34R, 9 G34V, 2 via DNA methylation) were included. The median age at diagnosis was 17 years (range, 2–45). Initial gross/near total resection (GTR/NTR) was achieved in 43% of patients. Radiation was given in 91% (85% focal irradiation), and initial chemotherapy was given in 87% [70% temozolomide-based (TMZ), 25% TMZ/lomustine, 5% non-TMZ]. Median OS was 24 months [interquartile range (IQR), 22–28] with a median PFS of 14 months (IQR, 12–19). Twelve patients (8%) were found to be long-term survivors (≥5 years). Exploratory multivariable analysis showed that adjuvant radiotherapy [HR, 0.076; 95% confidence interval (CI), 0.033–0.17] and achieving GTR/NTR compared with &lt; NTR (HR, 0.51; 95% CI, 0.33–0.78) were associated with improved PFS. Multivariable analysis showed improved OS with increasing age at diagnosis (HR, 0.70; 95% CI, 0.57–0.87), initial radiotherapy (HR, 0.38; 95% CI, 0.15–0.96), and initial GTR/NTR compared with &lt; NTR (HR, 0.60; 95% CI, 0.37–0.97). Conclusions: This cohort highlights prognostic factors for patients with DHG, H3 G34, and describes relapse patterns and therapy approaches. Clinical trials and prospective registries are needed to improve outcomes.
Strategies for Inclusive Practices in Clinical Procedure Training
Olson, Emily M. , Lui, Justin K. , Santhosh, Lekshmi , Camac, Erin , Garbarino, Alexander

Mayo Clinic

The Clinical Teacher | March 8, 2026 | Volume: 23 | Issue: 2 | Pages: No page available

10.1111/tct.70390 | PMID 41793375 Get It

Evaluating “brain permeability”: A critical issue for the development of therapeutic agents for primary and metastatic brain tumors
Grossman, Stuart A. , Barone, Amy , Strowd, Roy E, Rais, Rana , Duke, Elizabeth , Wearne, Emily , Price, Lauren , Hendrix, C. W., Schreck, Karisa C. , Lesser, Glenn J. , Sanai, Nader , Blakeley, Jaishri O, Nabors, Burt L., Sarkaria, Jann N, Peereboom, David, Schiff, D., Prowell, Tatiana M. , Elmquist, William F. , Hendrix, Craig W. , Strowd, Roy E. , Strowd, Roy E , Price, Lauren S L , Hendrix, Craig , Lesser, Glenn , Romo, Carlos , Portnow, Jana , Blakeley, Jaishri O , Kamson, David O , Nabors, Louis Burt , Searson, Peter C , Sarkaria, Jann N , Peereboom, David M , Schiff, David , Prowell, Tatiana M , Grossman, Stuart A , Romo, Carlos G. , Blakeley, Jaishri O. , Kamson, David , Nabors, Burt , Sarkaria, Jann N. , Peereboom, David M.

Mayo Clinic

Neuro-Oncology | March 7, 2026 | Volume: 28 | Issue: 7 | Pages: 1599-1611

10.1093/neuonc/noag051 | PMID 41818680 Get It

Abstract Current assessments of brain permeability rely predominantly on drug delivery to contrast-enhancing tumor regions. However, substantial portions of central nervous system (CNS) tumors reside within non-enhancing brain (NEB), where drug concentrations frequently remain subtherapeutic. This collaborative Adult Brain Tumor Consortium and Food and Drug Administration workshop aimed to identify criteria for defining NEB permeability to accomplish 2 critical objectives: (1) allocate clinical trial resources toward agents achieving therapeutic NEB concentrations and (2) minimize systemic toxicity when CNS benefit is improbable. The workshop systematically evaluated permeability assessment modalities, including drug physicochemical properties, in vitro blood-brain barrier models, and penetration into cerebrospinal fluid and normal rodent brain. Methodological approaches to determine requisite NEB drug concentrations and approaches to measuring NEB pharmacokinetics and pharmacodynamics were examined. This culminated in developing the Non-Enhancing Brain Permeability Index (NEBPI), which assigns therapeutic agents to 3 categories: sufficiently permeable, insufficiently permeable, or impermeable. The NEBPI provides a standardized framework to assist investigators and regulatory agencies to evaluate NEB penetration before human efficacy studies are initiated for agents that require direct tumor contact. Assessing NEB drug penetration is critical to improving outcomes in CNS tumors and reducing the incidence of brain metastases in systemic malignancies.
Diffusion MRI based biomarkers reveal a Prolonged Pre-Lesional Phase of Cerebral Small Vessel Disease
Vemuri, Prashanthi, Hu, Mingzhao, Kamykowski, Michael G. , Reid, Robert I. , Therneau, Terry M, Raghavan, Sheelakumari, Cogswell, Petrice M., Griswold, Michael, Windham, B. Gwen, Jack, Clifford R., Petersen, Ronald C., Graff-Radford, Jonathan, Raghavan, Sheelakumari , Reid, Robert I , Kamykowski, Michael G , Raghavan, Sheelakumari , Vemuri, Prashanthi , Hu, Mingzhao, Lundt, Emily S. , Therneau, Terry M. , Cogswell, Petrice M. , Windham, B. Gwen , Jack, Clifford R. , Petersen, Ronald C. , Graff‐Radford, Jonathan

Mayo Clinic

No container title available | March 7, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.03.03.709452 Get It

Abstract Background White matter hyperintensities (WMH) are widely used to assess cerebral small vessel disease (SVD) but reflect late-stage injury. Diffusion MRI based biomarkers have been proposed to capture earlier SVD-related microstructural damage but their temporal progression relative to WMH and the risk factors associated with this progression have not been explored. Methods We analyzed longitudinal neuroimaging data from 2,047 participants from a population-based cohort study (aged 49-101 years, 47% female). Using multi-output nonlinear mixed-effects models, we characterized the temporal progression of WMH and four diffusion MRI based biomarkers: fractional anisotropy of the genu of the corpus callosum (Genu-FA), peak width of skeletonized mean diffusivity (PSMD), free water (FW), and Arteriolosclerosis-score (ARTS). Models incorporated participant-specific time shifts, correlations between biomarkers, and effects of risk factors (sex, education, APOE ε4 status, and cardiometabolic conditions). Results ARTS, Genu-FA, FW, and PSMD became abnormal in 50% of the study population 16, 12, 10, and 7 years before WMH, respectively. Global markers (ARTS, FW, PSMD, WMH) were correlated, indicating shared substrates of widespread white matter injury. Genu-FA, a vascular risk microstructural injury biomarker, was weakly coupled with WMH and had an earlier but more linear worsening across adulthood. Cardiometabolic conditions predicted earlier worsening of all biomarkers. Females showed earlier WMH, Genu-FA, and ARTS abnormalities whereas males exhibited earlier PSMD and FW abnormalities. Conclusions Diffusion MRI based biomarkers capture microstructural injury at least a decade before appearance of WMH, revealing a prolonged phase of early SVD and highlighting their potential for SVD prevention.
Membrane Tension Integrates Physical and Signaling Cues to Gate Cell Fate Transitions
Ali, Gibran , Gibbard, D., Ghelfi, Elisa , Olson, Aaron, Cai, Junming, Balagtas, Aidan, Klein, Isaiah, Maccoux, Emily C., Han, Yulong, Miura, Akihiro , Guo, Ming, Glass, Ian A., Gibbard, Daniel, Maccoux, Emily, Mori, Munemasa, Brownfield, Douglas G , Guo, Ming , Mori, Munemasa , Brownfield, Douglas

Mayo Clinic

No container title available | March 5, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.03.04.708749 | PMID 41867811 Get It

Summary Physical forces shape cell behavior, yet how they integrate with signaling to control fate and disease remains unclear. The alveolar epithelium is patterned by FGF signaling and mechanical stretch, but how these cues specify AT1 and AT2 cells is poorly understood. Here we show that cell membrane tension (CMT) is a conserved regulator of epithelial fate in mouse and human lungs. CMT drops before differentiation and is spatially patterned, defining where bipotent progenitors acquire AT1 or AT2 identity. Lower CMT enhances FGFR2 endocytosis and ERK signaling to drive AT2 differentiation and permits architectural remodeling that enables stretch-mediated YAP/TAZ nuclear entry for AT1 maturation. β-catenin elevates CMT cell-intrinsically independent of its role in canonical WNT transcription, while embedding, osmotic compression, or fibroblast wrapping elevate CMT extrinsically. Combined intrinsic and extrinsic tension traps alveolar epithelial cells in a KRT8⁺ transitional state seen in fibrotic lungs. Membrane tension thus integrates physical and molecular cues linking morphogenesis to fibrosis. Graphical Abstract In Brief We identify a conserved drop in cell membrane tension (CMT) that gates epithelial fate transitions across mouse and human lungs. In bipotent progenitors, reduced CMT promotes Alveolar Type 2 (AT2) fate via FGFR2 endocytosis and ERK signaling, as well as Alveolar Type 1 (AT1) fate by enabling architectural remodeling required for YAP/TAZ nuclear entry. We further show that intrinsic β-catenin and extrinsic confinement cues, including mesenchymal contact, converge to elevate CMT, restricting differentiation and—in adult AT2s—inducing a KRT8⁺ transitional state associated with fibrosis. Highlights Cell membrane tension drops before differentiation and is required for AT1 and AT2 fate acquisition. Reduced tension enhances FGFR2 endocytosis and ERK signaling to drive AT2 specification. Reduced tension permits architectural remodeling and YAP/TAZ nuclear entry required for AT1 maturation. Intrinsic β-catenin and extrinsic confinement elevate CMT to restrict differentiation and together strongly induce a KRT8⁺ transitional state associated with fibrosis.
Across preclinical and clinical platforms, approved and investigational psychiatric drugs share pathways and associate with similar molecular functions
Su, Emily , Valencia, Nico Matthew S., Le, Jarod, Liu, Emily , Wilson, Jennifer L.

Mayo Clinic

Frontiers in Drug Discovery | March 4, 2026 | Volume: 5 | Issue: No issue available | Pages: No page available

10.3389/fddsv.2025.1686789 | PMID 42239657 Get It

Introduction Translating findings from cell and animal models to the clinic is difficult because these systems insufficiently capture human disease biology. Computational approaches, notably pathways modeling, have overcome interspecies differences by mapping shared signaling pathways between species. We considered whether this approach could be generalized to bridge animal and virtual drug screening data to effects measured in patients. We emphasized translational psychiatry datasets because of the unmet need for effective therapies. Methods We conducted three parallel analyses using published drug screening data in zebrafish, structure-function computational screening data, and clinically-reported efficacy data for experimental and approved antipsychotic drugs and predicted drug pathways using the PathFX algorithm Results Despite choosing screens developed for unique aspects of psychiatry and without careful curation of shared drugs, we found pathways associated with drugs that performed “well” across these distinct platforms—specifically, among drugs measured as favorable (expected to improve disease) or unfavorable (expected to aggravate disease) across screens, these drugs connected to distinct pathway proteins; however, these drugs are connected to similar protein families and shared Gene Ontology functional terms. By comparing screens, we discovered that favorable drugs may influence G-proteins, solute carrier family proteins, adrenoceptors, and steroid hydroxylase activity and that unfavorable drugs affect serotonin receptors and phosphodiesterase activity. Discussion This suggests that predictive platforms could emphasize functional information as features that could overcome differences in distinct screening platforms to eventually improve translational approaches.